World Lung 2024 – Lilly eyes a first-line KRAS triplet
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.